Buy direct from Zoetis with the same low prices available to everyone
- Prices are clearly visible for
all to see
- Best buy prices based on quantity ordered
- Promotions clearly listed
- Straight forward shopping experience
- Seamless delivery Australia-wide
- Multiple ways to place orders and pay account
- Easy access to technical knowledge
- Info on products and associated conditions and diseases
- Easy to find contact details and greater support
Australian veterinarians can now purchase our full range of products directly from Zoetis.
Zoetis Direct is a business-to-business initiative. Zoetis does not supply products directly to the general public.
VIDEO: OVERVIEW OF ZOETIS DIRECT
Zoetis Direct evolves the way we deliver value to you, your clinic and importantly to your patients. You will enjoy transparent pricing, a simple ordering system, seamless delivery and easy access to expert advice through our direct distribution commitment.
IsoFlo is a general inhalant anaesthetic agent. IsoFlo is a clear, colourless stable liquid containing no additives or chemical stabilisers for the generation of gaseous anaesthetic. Active Constituent: 100% Isoflurane.
Recommendations for use:
A potent non-irritant,
inhalantanaesthetic. It can be used for all types of veterinary surgery in horses, cats, dogs, ornamental birds, reptiles and small mammals. lsoFlo produces unconsciousness by its action on the central nervous system and is a good muscle relaxant for surgical procedures. It has negligible analgesic properties and consideration should be given to the analgesic requirements of the patient before recovery from anaesthesia takes place.
250 mL bottle
- IsoFlo is a potent, non-irritant general inhalant anaesthetic agent
- It can be used for all types of veterinary surgery for in cats, dogs, ornamental birds, reptiles, small mammals and horses.
- IsoFlo produces unconsciousness by its action on the central nervous system and is a good muscle relaxant for surgical procedures.
- IsoFlo may be used with other drugs commonly used in veterinary anaesthetic regimes. It has negligible analgesic properties and consideration should be given to the analgesic requirements of the patient before recovery from anaesthesia takes place.
lsoFloshould be administered using an accurately callibratedvaporiser in an appropriate anaesthetic circuit. Levels of anaesthesia may be altered rapidly and easily, lsoFlomay be administered in oxygen or oxygen-nitrous oxide mixtures.
The MAC (minimal alveolar concentration) in oxygen given below for the target species should be used as a guide only. The actual concentrations required in practice will depend on many variables including the concomitant use of other drugs and the clinical status of the patient.
Horse. MAC 1.31%. Induction: 3-5% (foals). Maintenance: 1.5-2.5%
Dog. MAC: 1.28%. Induction: up to 5%. Maintenance: 1.5-2.5%
Cat. MAC: 1.63%. Induction: up to 4%. Maintenance: 1.5-3%.
Ornamental birds. MAC: approx. 1.45%. Induction: 3-5%. Maintenance: 0.6-5%
Reptiles. MAC: not published. Induction: 2-4%. Maintenance: 1-3%.
Small mammals. MAC: 2.05% (rabbit), 1.34%. (mouse), 1.38-2.4% (rat). Induction: 2-3%. Maintenance: 0.25-2%.
In all species, recovery is normally smooth and rapid.
IsoFlo (isoflurane) should only be used in a vapouriser suitable for isoflurane with an appropriate anaesthetic circuit.
Store below 25 °C. Protect from direct sunlight and direct heat. Store in tightly closed original container.
Disposal of empty container by wrapping in paper and placing in
garbage. Alternatively, glass bottles should be completely emptied before disposal and placed in a glass recycle bin.
May irritate the eyes and skin. Do not swallow. Avoid contact with eyes and skin and ensure adequate ventilation during use.
Additional user safety
Eyes should be protected from splashes and plastic (not rubber) gloves should be worn.
Do not breathe the vapour. The recommended occupational exposure standard (OES) on an 8 hour time weighted basis is 50ppm (UK standards).
Operating rooms should be provided with adequate ventilation and active extraction to prevent the accumulation of Isoflurane vapours. Induction and recovery areas should be well ventilated.
Care should be taken when dispensing IsoFlo into the vaporiser. Spillage should be contained or removed immediately, using sawdust, sand or other inert absorbents, to a well ventilated place.
Repeated exposure to halogenated anaesthetics has been linked to increased miscarriages in personnel of operating theatres.
Potentially pregnant theatre staff should minimise exposure to the vapours.
First Aid Statement
If poisoning occurs, contact a doctor or Poisons Information Centre. Phone Australia 131126.
In the event of severe acute accidental exposure remove the operator from the source of exposure, seek urgent medical assistance and show the label. Wash any splashes from skin immediately with soap and water. Contaminated eyes should be washed with water for 10 minutes.
Registered label warnings
Treated animals MUST NOT be used or processed for human consumption.
Treated animals MUST NOT be used or processed for human consumption.
This product is contraindicated for use in animals with a known sensitivity to isoflurane or with a known susceptibility to malignant hypothermia.
IsoFlo causes dose-related respiratory and cardiovascular depression. It is important that respiration and pulse should be monitored for both rate and character. Respiratory arrest should be treated by assisted ventilation with air or, preferably, with oxygen supplementation. It is important that a patent airway be maintained and adequate tissue oxygenation achieved throughout the period of anaesthesia. Should cardiac arrest occur, full cardiopulmonary resuscitation methods should be applied. Cardiac arrhythmias have been reported very occasionally. However, IsoFlo has a weaker sensitising action on the myocardium, to the effects of dysrhythmogenic circulating catercholamines, than halothane.
When using isoflurane to anaesthetise an animal with a head injury, consideration should be given as to whether artificial ventilation is appropriate to maintain normal CO2 levels, so that cerebral blood flow does not increase.
In man, the action of muscle relaxants, especially those of the non-depolarising type such as atracurium, pancuronium or vecuronium is enhanced by isoflurane. Similar to potentiation might be expected to occur in the target species, although there is little direct evidence to this effect.
The concurrent use of sedative or analgesic drugs is likely to reduce the level of isoflurane required to induce and maintain anaesthesia. For example, opiates, alpha-2-agonists, acepromazine, and benzodiazepines have been reported to reduce the MAC values. Particular caution should be exercised if administering a midazolam-ketamine combination to an animal already anaesthetised with isoflurane.
Isoflurane has been reported to interact with dry carbon dioxide absorbents to form carbon monoxide. In order to minimise the risk of formation of carbon monoxide in breathing circuits and the possibility of elevated carboxyhaemoglobin levels, carbon dioxide absorbents should not be allowed to dry out.
IsoFlo has been safely used for anaesthesia during Caesarean section in the dog and the cat. Reproduction studies have been performed in mice, rats and rabbits with no evidence of foetal malformation attributable to isoflurane at clinically relevant concentrations. However, fully comprehensive data concerning its use in pregnant, breeding or lactating animals of all target species have not been obtained.
- Costa Rica
- Czech Republic
- New Zealand
- South Africa
- South Korea
- United Kingdom
- United States